Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281755777> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4281755777 endingPage "A19" @default.
- W4281755777 startingPage "A19.1" @default.
- W4281755777 abstract "Introduction No evidence of disease activity (NEDA; no relapses, MRI activity, or Expanded Disability Status Scale worsening) is considered a multiple sclerosis (MS) treatment goal. We assessed the independent contributions of NEDA components, serum neurofilament light (sNfL), brain parenchymal fraction (BPF), and other clinical outcomes in defining disease control with natalizumab. Methods We used AFFIRM data from 792 patients to assess change (baseline to year [Y] 2) in NEDA com- ponents, worsening of Paced Auditory Serial Addition Test, 9-Hole Peg Test, Timed 25-Foot Walk, change (Y1-Y2) in BPF, and Y2 sNfL levels. Comparisons included odds ratios (ORs) for natalizumab vs placebo and area under the receiver-operating characteristic curve (AUC). Results No MRI activity (OR=9.3; AUC=0.73; P<0.0001 vs. placebo), no relapses (2.7; 0.62; P<0.0001), and sNfL <8 pg/mL (4.1; 0.67; P<0.0001) had the strongest association with natalizumab. The best-fit multivariate logistic regression model included no MRI activity (OR=7.6; 95% CI=5.0–11.5; P<0.0001), sNfL (3.1; 2.2–4.5; P<0.0001) and no relapses (2.1; 1.5–3.0; P<0.0001). Conclusion MRI activity, sNfL, and relapses had the strongest natalizumab treatment association over 2 years in AFFIRM. sNfL may be useful in defining disease control with natalizumab. *Additional authors: Richard A. Rudick (Biogen, Cambridge, MA, USA), Al Sandrock (Biogen, Cambridge, MA, USA). Support: Biogen. Disclosures: Included on poster. g.giovannoni@qmul.ac.uk" @default.
- W4281755777 created "2022-06-13" @default.
- W4281755777 creator A5005475237 @default.
- W4281755777 creator A5007615278 @default.
- W4281755777 creator A5015754502 @default.
- W4281755777 creator A5031075667 @default.
- W4281755777 creator A5039277435 @default.
- W4281755777 creator A5047263299 @default.
- W4281755777 creator A5061851273 @default.
- W4281755777 creator A5063009739 @default.
- W4281755777 creator A5067110474 @default.
- W4281755777 date "2022-05-27" @default.
- W4281755777 modified "2023-09-27" @default.
- W4281755777 title "018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab" @default.
- W4281755777 doi "https://doi.org/10.1136/jnnp-2022-abn.57" @default.
- W4281755777 hasPublicationYear "2022" @default.
- W4281755777 type Work @default.
- W4281755777 citedByCount "0" @default.
- W4281755777 crossrefType "journal-article" @default.
- W4281755777 hasAuthorship W4281755777A5005475237 @default.
- W4281755777 hasAuthorship W4281755777A5007615278 @default.
- W4281755777 hasAuthorship W4281755777A5015754502 @default.
- W4281755777 hasAuthorship W4281755777A5031075667 @default.
- W4281755777 hasAuthorship W4281755777A5039277435 @default.
- W4281755777 hasAuthorship W4281755777A5047263299 @default.
- W4281755777 hasAuthorship W4281755777A5061851273 @default.
- W4281755777 hasAuthorship W4281755777A5063009739 @default.
- W4281755777 hasAuthorship W4281755777A5067110474 @default.
- W4281755777 hasConcept C126322002 @default.
- W4281755777 hasConcept C142724271 @default.
- W4281755777 hasConcept C151956035 @default.
- W4281755777 hasConcept C203014093 @default.
- W4281755777 hasConcept C204787440 @default.
- W4281755777 hasConcept C27081682 @default.
- W4281755777 hasConcept C2779134260 @default.
- W4281755777 hasConcept C2780640218 @default.
- W4281755777 hasConcept C2781004633 @default.
- W4281755777 hasConcept C58471807 @default.
- W4281755777 hasConcept C71924100 @default.
- W4281755777 hasConcept C76318530 @default.
- W4281755777 hasConceptScore W4281755777C126322002 @default.
- W4281755777 hasConceptScore W4281755777C142724271 @default.
- W4281755777 hasConceptScore W4281755777C151956035 @default.
- W4281755777 hasConceptScore W4281755777C203014093 @default.
- W4281755777 hasConceptScore W4281755777C204787440 @default.
- W4281755777 hasConceptScore W4281755777C27081682 @default.
- W4281755777 hasConceptScore W4281755777C2779134260 @default.
- W4281755777 hasConceptScore W4281755777C2780640218 @default.
- W4281755777 hasConceptScore W4281755777C2781004633 @default.
- W4281755777 hasConceptScore W4281755777C58471807 @default.
- W4281755777 hasConceptScore W4281755777C71924100 @default.
- W4281755777 hasConceptScore W4281755777C76318530 @default.
- W4281755777 hasIssue "6" @default.
- W4281755777 hasLocation W42817557771 @default.
- W4281755777 hasOpenAccess W4281755777 @default.
- W4281755777 hasPrimaryLocation W42817557771 @default.
- W4281755777 hasRelatedWork W2025498382 @default.
- W4281755777 hasRelatedWork W2164556363 @default.
- W4281755777 hasRelatedWork W2171288501 @default.
- W4281755777 hasRelatedWork W2386767720 @default.
- W4281755777 hasRelatedWork W2771212127 @default.
- W4281755777 hasRelatedWork W3145338295 @default.
- W4281755777 hasRelatedWork W4221111185 @default.
- W4281755777 hasRelatedWork W4254560717 @default.
- W4281755777 hasRelatedWork W4307380592 @default.
- W4281755777 hasRelatedWork W4363678234 @default.
- W4281755777 hasVolume "93" @default.
- W4281755777 isParatext "false" @default.
- W4281755777 isRetracted "false" @default.
- W4281755777 workType "article" @default.